Merck’s Sac-TMT Phase 3 Trial Hits Dual Endpoints in Endometrial Cancer
Merck announced TroFuse-005, a global Phase 3 trial, met its dual primary endpoints of overall survival and progression-free survival for sacituzumab tirumotecan (sac-TMT) versus physician’s choice chemotherapy in advanced or recurrent endometrial cancer after platinum-based therapy and anti‑PD-1/L1 therapy; interim analysis showed statistically significant OS and PFS improvements and a positive objective response rate, with a safety profile consistent with prior studies. The TroFuse program spans 17 global Phase 3 trials across multiple tumor types, highlighting Merck’s leadership in TROP2-directed ADCs in women’s cancers.